Identification of distinct and shared biomarker panels in different manifestations of cerebral small-vessel disease through proteomic profiling
Nature Aging, 2026
Hristovska I., Pichet Binette A., Kumar A., Wennström M., Gaiteri C., Karlsson L., Strandberg O., Janelidze S., van Westen D., Stomrud E., Palmqvist S., Ossenkoppele R., Mattsson-Carlgren N., Vogel J., Hansson O.
| Disease area | Application area | Sample type | Products |
|---|---|---|---|
Neurology Neurovascular Diseases | Pathophysiology Patient Stratification | Plasma Csv | Olink Explore 3072/384 Olink Explore HT T Targe T96 |
Abstract
The pathophysiology underlying various manifestations of cerebral small-vessel disease (cSVD) remains poorly understood. Using high-throughput proteomics, we identified common and distinct proteomic signatures of white matter lesions (WMLs), microbleeds, infarcts and their subtypes, measured in 1,670 living patients. Across all cSVD manifestations, markers of extracellular matrix dysregulation and vascular remodeling were increased, including ELN, POSTN, CCN2 and especially MMP12, implicating endothelial and smooth muscle cells of the brain. These proteins were validated in cerebrospinal fluid from two additional datasets, and a subset detected in plasma predicted future cerebrovascular events in the UK Biobank better than risk scores currently used in clinical practice. Analysis focusing on WMLs found microglial-associated proteins associated with faster WML progression, whereas specific neuron-derived proteins mediated the link between WMLs and longitudinal cognitive decline. These data provide a comprehensive atlas of cSVD biomarkers, and our findings provide a promising roadmap for future diagnostics and therapeutics.